[ad_1]
Summary
[¡Los resultados de las negociaciones del seguro médico de 2020 se publican oficialmente! Las acciones farmacéuticas de alto crecimiento llegan al norte con más de mil millones de fondos para tomar 3 acciones]Negotiation results show that three national PD-1s, including Junshi Biologics’ treprizumab, BeiGene’s tislelizumab, and Hengrui Medicine’s El Karelizumab were successfully negotiated and included in health insurance. Judging by today’s share price action, Junshi Biotech fell slightly 0.06% at the close and Hengrui Pharmaceuticals fell 3.49%; BeiGene’s shares in Hong Kong rose once more than 6% and fell to 0.95% in recent trading.
On December 28, the 2020 National Health Insurance Drug List was published and will be officially implemented on March 1 of next year.
The National Medical Security Administration held today in BeijingPress conferenceMeans, medium,There are 119 new drugs shortlisted, includingnegotiation96 kinds of imported exclusive drugs and 23 kinds of directly imported non-exclusive drugs.Experts said this batch of recently shortlisted drugs has achieved “Higher cost performance”。
According to the official website of the National Medical Security Administration, a total of 162 drugs were negotiated in this setting and 119 negotiations were successful.The negotiation success rate was 73.46%,The average price of successfully negotiated drugs was reduced by 50.64%.
New National Catalog of Health Insurance
It is estimated that it will reduce the burden of patients by 28 billion yuan.
By adapting this catalog, “National Basic Medicalinsurance、Work injuryinsuranceAnd fertilityinsuranceThe total number of drugs in the “Drug Catalog (2020)” is 2,800, of which 1,426 are Western drugs and 1,374 are Chinese proprietary drugs. There are still 892 kinds of Chinese medicinal herbs in the catalog with no adjustments. In general, this setting has the following characteristics:
1. Unlike previous rounds of adjustments that included “all drugs on the market” in the scope of the review, the declaration system was implemented for the first time this year, that is, drugs outside the catalog that meet the conditions listed in this year’s plan of adjustment may be included in the scope of adjustment. The scope of adjustment for non-catalog drugs has transitioned from “sea pick” to “preferred”.
2. Compared to previous years, the number of drugs transferred in the price cuts in this negotiation is the highest and the treatment fields the most benefited. The 119 drugs recently added to this catalog fit involve a total of 31 clinical groups, representing 86% of all clinical groups, patients benefit from a wide range of patients, and their sense of profit will be even greater.
3. The first attempt to negotiate a reduction in the price of catalog drugs has significantly improved the economy. The experts for the review were selected according to procedurepriceOr the cost is too highbackgroundA large number of 14 unique drugs are used for price reduction negotiations, and the annual sales of these drugs exceed 1 billion yuan.
4. At this setting, medications such as ribavirin injection and arbidol granules have been added to the catalog. The drugs listed in the latest version of the National New Coronary Pneumonia Diagnosis and Treatment Program have been included in the National Health Insurance Catalog, which will help prevent and control the epidemic with practical actions.
According to reports, of the patient burden,Price reduction and medical insurance through this negotiationRefundThe cumulative patient burden is expected to decline by about 28 billion yuan in 2021.
Experts in the field of health insurance negotiations spare no effort to “negotiate”
According to CCTV News, in this year’s health insurance negotiations, expert negotiators and pharmaceutical companies came and went on his behalf, repeatedly “PK” and “cutting” countless “famous scenes”. On the Kangai injection negotiation site For cancer treatment, representatives of pharmaceutical companies in Northeast China met with the expert negotiator and said “humbly”:companyI do not know how to say it “. Faced with the cautious price cut by representatives of the pharmaceutical companies, the negotiator said with a smile: “The price cut is not like squeezing toothpaste. It is not easy to negotiate! “
Tislelizumab is reported to have become the first PD-1 drug to enter health insurance this year, and its indications cover a variety of cancers including lung and liver. National Health Safety AdministrationServiceDirector Xiong Xianjun said we have 7 PD-1productWhen participating in the negotiation, three PD-1s of domestic production negotiated successfully and the price reduction is still very large.Basically around 80%.
The results of the negotiations showed that three PD-1s of domestic production, includingJunshi BioFrom triprolizumab,BeiGeneTislelizumab andHengrui MedicineCarrelizumab was successfully negotiated for inclusion in health insurance. Judging by the current behavior of the share price,Junshi BioAt the close, it fell slightly 0.06%,Hengrui MedicineDown 3.49%;BeiGeneHong Kong StockAt one point, it rose more than 6% and fell back to 0.95% in recent trades.
High-growth pharmaceutical stocks list going forward
HuachuangValuesAnnual health insurance negotiations are believed to have gradually normalized, the willingness and speed of innovative products to enter the health insurance negotiations are increasing, and health insurance negotiations have turned into innovative drugs.Heavy volumeImportant catalyst. With the gradual implementation of the policy, the uncertainty of the pharmaceutical industry will gradually disappear.The pharmaceutical industry will usher in a valuation change, high prosperityPerformanceThe fast growing subsectors will receive more attention.
Using unanimous forecast data from 5 or more institutions, the Securities Times · Databao has ranked the pharmaceutical stocks that are expected to achieve high growth in the next two years for readers’ reference. Data visualization,Share49 pharmaceutical stocks this year and nextNet profitThe increase is expected to reach more than 20%, Eight hundred billionMarket valueOf the top finalists, includingHengrui Medicine、Mindray Medical、Ophthalmology Aier、WuXi AppTec、Zhifei、Changchun High Tech、Pien Tze Huang、Kangtai BioWait.
Since December, the average increase of the 49 shares mentioned above is 5.81%, higher than the same periodShanghai indexMore than 5 percentage points。Kangtai Bio, Hengrui Pharmaceutical,Kanglong Chemistry、Opcom、WuXi AppTecOther stocks rose more than 20%, the leader in vaccinesKangtai BioThe cumulative increase of 31.29% ranked firstDuring this period, some top-line pharmaceutical stocks gainedCapital to the northAdd warehouseThe data shows that according toAgreementRough calculation of the average price, northmoneyThere are 12 stocks that have increased their holdings by more than 100 million yuan, of which,Hengrui MedicineThe capital increased by 4.99 billion yuan to top the list. Followed byMindray Medical、Changchun High Tech, The amount of stakes exceeded one billion yuan.
(Article source: treasure trove of data)
(Responsible editor: DF537)
I solemnly declare: The purpose of this information is to spread more information, and it has nothing to do with this booth.
[ad_2]